News & Updates

Show Multimedia Only

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

27 Aug 2025 by

In Asian patients with severe chronic rhinosinusitis with nasal polyps who are receiving daily intranasal corticosteroid, add-on treatment with the novel monoclonal antibody stapokibart helps shrink polyp size and bring down the severity of symptoms, as shown in the phase III CROWNS-2 study conducted in China.

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

27 Aug 2025

Treatment further worsens physical function in NSCLC

26 Aug 2025

Patients with non-small cell lung cancer (NSCLC) already have poorer physical health and quality of life compared with healthy individuals. Treatment for this type of cancer makes these issues even worse, with patients becoming less physically active, according to a study.

Treatment further worsens physical function in NSCLC

26 Aug 2025

Aspirin cuts risk of death in critically ill patients with COPD

25 Aug 2025

In critically ill patients with chronic obstructive pulmonary disease (COPD), aspirin use appears to improve survival, with reduced in-hospital mortality and fewer ICU readmission, according to a retrospective study.

Aspirin cuts risk of death in critically ill patients with COPD

25 Aug 2025

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025 by

A lung nodule surveillance programme at Queen Mary Hospital (QMH) facilitates diagnosis of early-stage lung cancer. Data from the programme’s first year of implementation showed a higher proportion of early-stage lung cancer diagnoses compared with the Hong Kong Cancer Registry’s (HKCR) annual report.

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

20 Aug 2025

The use of fenestrated stents results in longer patency, fewer complications, and improved biomechanical performance than conventional silicone stents, without compromising the structural integrity of the stent, according to a study.

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

20 Aug 2025

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025 by

A 77-year-old male chronic smoker with a history of diabetes mellitus, hypertension, coronary artery disease treated with stenting to left circumflex artery and ramus intermediate artery in 2015, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) presented on 19 January 2024 with shortness of breath (SOB) on exertion, which began following an episode of COVID-19 in May 2023 and worsened after a subsequent COVID-19 episode in April 2024. Before the two COVID-19 episodes, the patient had good exercise tolerance and could manage a 1-hour hike.

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025 by

A 65-year-old male with good past health presented in June 2024 with a 1-month history of cough.

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Sotatercept, a first-in-class activin signalling inhibitor for pulmonary arterial hypertension (PAH), is approved in Hong Kong in August 2025, following regulatory approvals in Macau, the US, and the EU in February 2025.

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

20 Aug 2025

Once-daily, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) outperforms twice-daily, single-inhaler triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/ FORM) in the treatment of chronic obstructive pulmonary disease (COPD), two recent real-world comparative effectiveness studies have found.

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

20 Aug 2025

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis

19 Aug 2025

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) can set up an immunosuppressive microenvironment in the lung via arginase-1 (ARG-1) bronchiectasis, which is linked to clinical outcomes and response to antibiotic treatment among patients with bronchiectasis, suggests a study.

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis

19 Aug 2025

News & Updates

Showing Respirology articles

Showing

Specialty:

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

Treatment further worsens physical function in NSCLC

Treatment further worsens physical function in NSCLC

Aspirin cuts risk of death in critically ill patients with COPD

Aspirin cuts risk of death in critically ill patients with COPD

Lung nodule surveillance programme helps detect early-stage lung cancer

Lung nodule surveillance programme helps detect early-stage lung cancer

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

First experience with sotatercept for pulmonary arterial hypertension in Southern China

First experience with sotatercept for pulmonary arterial hypertension in Southern China

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Sotatercept: A first-in-class PAH medication approved in HK

Sotatercept: A first-in-class PAH medication approved in HK

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis